Personalized Healthcare in Autoimmune Diseases - Genomic Biomarkers for Pharmaceutical Development - page 69

[68] Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFNβ is associated with poor treatment
response in patients with multiple sclerosis. PLoS One 2011;6(5):e19262. http://dx.doi.org/10.1371 / journal.
pone.0019262 . [Epub 2011 May 13].
[69] Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta
in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16(4):406-12. http://dx.doi.
org/10.1038 / nm.2110 . [Epub 2010 March 28].
[70] Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFN-β-1a in relaps-
ing-remitting MS. Neurology 2012;79(6):531-7.
[71] Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of
cell cycle arrest and death. Cancer Res 2003;63(19):6424-31.
[72] Schoenemeyer A, Barnes BJ, Mancl ME, et al. The interferon regulatory factor, IRF5, is a central mediator of
toll-like receptor signaling. J Biol Chem 2009;284:2767-77.
[73] Hu G, Barnes BJ. IRF5 is a mediator of the death receptor-induced apoptotic signaling pathway. J Biol Chem
2009;284:2767-77.
[74] Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) reg-
ulates splicing and expression and is associated with increased risk of systemic lupus erythemathosus. Nat
Genet 2006;38:550-5.
[75] Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr
Opin Immunol 2006;18:676-82.
[76] Rullo OJ, Woo JM, Wu H, et al. Association of IRF5 polymorphisms with activation of the interferon-α path-
way. Ann Rheum Dis 2010;69:611-17.